I

Idera Pharmaceuticals Inc
F:HXXB

Watchlist Manager
Idera Pharmaceuticals Inc
F:HXXB
Watchlist
Price: 2.8 EUR
Market Cap: 174.4m EUR

EV/EBIT
Enterprise Value to EBIT

-10.3
Current
-9.5
Median
5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-10.3
=
Enterprise Value
172.6m EUR
/
EBIT
-19.5m USD
EBIT Growth EV/EBIT to Growth
US
I
Idera Pharmaceuticals Inc
F:HXXB
Average EV/EBIT: 18.8
Negative Multiple: -10.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 128.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.9
17%
1.2
AU
CSL Ltd
ASX:CSL
23.3
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -301.1 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A